Trichostatin A (TSA) 化学構造
分子量: 302.4

高品質保証

カスタマーフィードバック(4)

MSDS

製品説明

  • Compare HDAC Inhibitors
    HDAC製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法
  • Trichostatin A (TSA)のメカニズム

製品の説明

生物活性

製品説明 Trichostatin A (TSA)は一種のHDAC阻害剤で、無細胞試験でIC50値が1.8 nM程度です。
ターゲット

HDAC

IC50

~1.8 nM [1]

In vitro試験 Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HEK 293 MnXOSpVv[3Srb36gRZN{[Xl? MYewMlfPxE1? MlrLNlRp M3rYW4V1cGGwb3y= MnrI[Y5p[W6lZYOgSW5iSyCjY3X0fYxifGmxbjDhcoQhcW6lcnXhd4V{KEWQYVOgZYJ2dmSjbnPlJIlvKHSqZTD0c5RidCClZXzsJIx6e2G2ZTDhcoQh[XRidHjlJINmdGxic4Xy[oFk\Q>? MlvsNlU4QDdyN{m=
TE13 MV;GeY5kfGmxbjDBd5NigQ>? NVG5ZpFOOC5|zszN NWKxUIJVOjSq NFvOZ2F2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> NGPOdlczPTV5OU[2OS=>
TE13 NUPoO4IxSXCxcITvd4l{KEG|c3H5 MXywMlPPxE1? Mm\MNlRp NE\PZlBqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w M1KwSFI2PTd7Nk[1
MEFs MXXGeY5kfGmxbjDBd5NigQ>? NXfFbFVYPc7:TR?= NWDJdFc{OT[q NVHydZh6cW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w MX:yOVQ5OjZ|NB?=
SW480  MmTrSpVv[3Srb36gRZN{[Xl? Mn:3NE4y|ryP NEXOU5o1QGh? MoD0SG1UVw>? NVLxRoFiemW4ZYLz[ZMhTU2W MnuyNlU1OzR7OUe=
PC3  MmnSSpVv[3Srb36gRZN{[Xl? NX73fm5xOC5zzszN NFzPWWM1QGh? MVjEUXNQ MkDsdoV3\XK|ZYOgSW1V M17PZlI2PDN2OUm3
SW480  M3j5OGZ2dmO2aX;uJGF{e2G7 M2XIe|AvOc7:TR?= MkPpOFhp MYTEUXNQ MUfheJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? NVqxW|R6OjV2M{S5PVc>
PC3  MXfGeY5kfGmxbjDBd5NigQ>? M1\FN|AvOc7:TR?= Mn;IOFhp Mn\0SG1UVw>? NEPWVm9ifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MnO5NlU1OzR7OUe=
SW480  M4nCRWZ2dmO2aX;uJGF{e2G7 NVnwO|RuOC5zzszN NV\ldIxUPDiq MUXEUXNQ MoX3bY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NULyTHREOjV2M{S5PVc>
PC3  MXXGeY5kfGmxbjDBd5NigQ>? MV6wMlHPxE1? Ml;IOFhp NIP2e45FVVOR NGnmcotqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ NF\1fHEzPTR|NEm5Oy=>
A431 MljKRZBweHSxc3nzJGF{e2G7 MmrMNk8yOC93MD:xNFBvVQ>? M13WeFQ5cA>? Mnq3SG1UVw>? NWfsVmtLcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To NY\jbVlIOjV|N{GwOlk>
A431 NILWbG9HfW6ldHnvckBCe3OjeR?= M1LpNVUxdk1? MVuyM|YwOTJxMkTo MYDEUXNQ NVewUWRC[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u Mm\JNlU{PzFyNkm=
MDA-MB-231 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O0XFAuPjBybl2= NGDDOpQzPGh? NYHFW2lHTE2VTx?= NGj4U|JKSzVyIH;mJFExOG6P MojNNlUyQTJ5MkG=
MCF7 M4Habmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjsT2MxNTZyMH7N MV:yOIg> MkHOSG1UVw>? NEfnU|JKSzVyIH;mJFc2dk1? M4X0PFI2OTl{N{Kx
SKOV-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[xMVEx|ryP MkHRNlRp NHvZeVBFVVOR NGj5[5VKSzVyIH;mJFUvPs7:TR?= MYqyOVE3QTR7MR?=
A549 NWHhS2dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fKXlEuOTEQvF2= MV6yOIg> MUDEUXNQ MYHJR|UxKG:oIEOuNu69VQ>? Mn;KNlUyPjl2OUG=
SKOV-3 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[wMlEuOc7:TR?= NEjGT3g1QGh? MlGwSG1UVw>? NVvMOXBwUUN3MDDv[kAxNjgQvF2= MUWyOVE3QTR7MR?=
A549 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrMfmU4OC5zLUJOwG0> Ml[2OFhp MnrVSG1UVw>? NX36eJlGUUN3MDDv[kAxNjJ6zszN MnTnNlUyPjl2OUG=
SKOV-3 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuwMlAyNTBwOd88US=> MlTLO|Jp NITT[IJFVVOR NWDlfYE2UUN3MDDv[kAxNjN{zszN NWjLeFR6OjVzNkm0PVE>
A549 NEP4NWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGwMlAyNTBwOd88US=> MnfRO|Jp NGf4dZlFVVOR M2C4UGlEPTBib3[gNE4xPs7:TR?= NIDKV2wzPTF4OUS5NS=>
HeLa M1XJUGZ2dmO2aX;uJGF{e2G7 NEjFUmIzPTCwTR?= NFXzb24yPmh? MVjEUXNQ MnT2bY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= MXmyOVEyPjZ6OB?=
CNE2 M{TDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTmRWoyODBvNkCwcm0> MViyOE81QC95Mni= MVvpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnTQNlQ6Pjl7MEG=
PC3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYeydVBoOTByLUGwNFBvVQ>? NIjU[IUzPGh? M2jocGlEPTBib3[gN|Axdk1? MlHPNlQ5PTR4NUi=
LNCaP NVv4[Y1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWSw[5VtOTByLUGwNFBvVQ>? M4[xcVI1cA>? MnfqTWM2OCCxZjCzNFBvVQ>? NWXUdmVkOjR6NUS2OVg>
HeLa  MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG2bIgz|ryP MVu0PIg> NFXYUZNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl NGTNPZIzPDh2NkGzOS=>
HMEC-1  NUHUO5FITnWwY4Tpc44hSXO|YYm= MV6zNFBvVQ>? MVuyOIg> MnjXbY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> NEHZWlczPDdzME[zNS=>
HeLa NEDieHVHfW6ldHnvckBCe3OjeR?= MXuxcW0> NF3hOY0xNjWq NYrPVmd7[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 NXjBRpJtOjR5MEe0O|Q>
ACP02 M4jlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2CzSlI2OC9|NUCvOVAxdk1? M{jnbVI1cA>? MmnS[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? MWOyOFY3QDV2Nx?=
ACP03 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDZfo55OjVyL{O1NE82ODCwTR?= NHLDUlYzPGh? NYPNVY9b\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MX6yOFY3QDV2Nx?=
U87 GBM MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ToVFExOC9|MECvOVAxKG6P NXfve2VxPzJiaB?= M1m3clExOCViZYToZY5wdA>? M2XifZJm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=> MYGyOFQ3PDh2MR?=
U87 GBM MojlSpVv[3Srb36gRZN{[Xl? NUjw[lVXOTByL{WwNEBPdQ>? MlLzOFghcA>? NU\Keo5COTByJTDleIhidm:u M1n3TWlv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>? NHK2R5kzPDR4NEi0NS=>
RPE M{mxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;aNE4zNzBwND:wMlgwOSEQvF2= M1\rNlI1NzR6L{eyJIg> NGLQZ3pFVVOR M1j0NIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 Mm[5NlQ1PTZ4MEK=
HT29  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:yTFE5OCCwTR?= NXXtSHpyPzJiaB?= MoXzTWM2OCCxZjCxPFAhdk1? NXTkeWpsOjR|NkiyOlU>
hMSCs MoWySpVv[3Srb36gRZN{[Xl? NED1XY83NjJ3IH7N M1;T[|I1KGh? NIHBUmlFVVOR MXPzeIFjcWyrenXzJGhqe3SxbnWgRYNmfHmuYYTpc44h[W6mIITo[UBGgHC{ZYPzbY9vKG:oIGDseZJqeG:2ZX70JGdmdmW| MViyOFMyOjN3Nh?=
Huh7  MW\GeY5kfGmxbjDBd5NigQ>? MYmwMlEwOC53L{GuNEDPxE1? NEPkcXIzPGh? MWjzeZBxemW|c3XzJHlVUESFMjDn[Y5mKGW6cILld5Nqd25? MViyOFI3QTZ5Mh?=
SKOV3 NIDye5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjC[nBROC5yNT2yJO69VQ>? NHu3b5cyOC9{ND:0PEBp M4fDZmROW09? NH7sSGpu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NXzzO25lOjR{MkO4NFE>
A2780 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjwSHkxNjB3LUKg{txO M4HSfVExNzJ2L{S4JIg> M361dmROW09? MWTt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MWmyOFIzOzhyMR?=
SRA01/04  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnkNE4zKM7:TR?= NFLFVY81QCCq Mo[zSG1UVw>? M1X6epN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ NVLDS5NvOjRzNUe4O|g>
HLEB3 M2myfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fET|AvOiEQvF2= NEjFS|Y1QCCq M2rONWROW09? M2DOTJN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ Mnz5NlQyPTd6N{i=
SRA01/04  Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{izdVAvPC9yLkig{txO MlzIOFghcA>? NWfISYVjTE2VTx?= MULpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NEXpV2czPDF3N{i3PC=>
HLEB3 M1vr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\GOlAvPC9yLkig{txO NV;ibGl4PDhiaB?= MnPWSG1UVw>? MXfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M4jHb|I1OTV5OEe4
HCT116 NHLxU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MViwMlIh|ryP M2CwNVEzKGh? M2HXSIVvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u M1\2eVI1OTJ{MkOx
CA46 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3wZnA{NzZxMUKvNlQwPDhibl2= M3jtc|Q5KGh? NES5blVqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi M2fvUFI1ODZ2OUWx
PMNs M3:4eGZ2dmO2aX;uJGF{e2G7 M4OxW|MxKG6P NFq0bHc1QCCq NFq4VG5qdmirYnn0d{Bm\m[ncn;jfZRwe2m|LDDISGFEKGGldHn2bZR6KGGwZDDSZYMh[WO2aY\peJk> Mn;qNlM6QDh4MUe=
H1299 NV:0bmJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nLPFHDqM7:TdMg M1vCd|I1NzR6L{eyJIg> MVfleIhidm:u M4nWOolv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? NYrSb3NXOjN7MU[2NFk>
A549 NWTId2VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGySGk5OC5{NT:wMlUwOSEQvF2= NFfNfmkzPC92OD:3NkBp MnHy[ZRp[W6xbB?= NELkc|hqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MYiyN|g3Pzl7MR?=
H1299 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:5NFQ2OC5{NT:wMlUwOSEQvF2= NVXhUY1TOjRxNEivO|IhcA>? NUS4empM\XSqYX7vcC=> MXnpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MkD6NlM5Pjd7OUG=
A549 Mny4RZBweHSxc3nzJGF{e2G7 M2T4dFAvPS9zIN88US=> MkjVOFghcA>? MWTleIhidm:u NHL6ZnhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M2TXSVI{QDZ5OUmx
H1299 MVnBdI9xfG:|aYOgRZN{[Xl? MXuwMlUwOSEQvF2= NYPKb2lrPDhiaB?= MlL3[ZRp[W6xbB?= MVzpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUWyN|g3Pzl7MR?=
SUM149PT MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTyNk84NjVxMUCg{txO MkD3OFghcA>? NGHO[o5FVVOR NHvO[3pqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= NVHoZ3VUOjN5OUK2N|g>
SUM190PT MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3kPJc2OC9zMECvNlUxKG6P MoTFOFghcA>? M17mXWROW09? M{\ndIlv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? NUHHV45bOjN5OUK2N|g>
HCT1 NXPsfGtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHoNE4zNzFwMD:1MlAh|ryP Mn;zNVIwOjRxM{[vOFghcA>? M2nDUIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M{XFcVI{PzdyMECw
Lovo MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWbFAvOi9zLkCvOU4xKM7:TR?= M2rVVlEzNzJ2L{O2M|Q5KGh? NFu4VmNqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M{K1UVI{PzdyMECw
AGS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnIVVJyOC5yMUWtNUDPxE1? MnX6O|IhcA>? MkCybY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MXKyN|c1PTB{NB?=
Huh7 NFXsVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDLNUDPxE1? NH36fIQzPCCq MX3EUXNQ NIXLOm1z\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>? NXfMcpg3OjN4NEO5N|M>
ECC1 MWDGeY5kfGmxbjDBd5NigQ>? NF;r[nA2ODBibl2= Mmq3OUBl NUD4RnIxTE2VTx?= MYnpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? M3fsRVI{PTNyN{[5
HEC1A NUj6ZpdNTnWwY4Tpc44hSXO|YYm= MoOyOVAxKG6P MmPHOUBl Mlv1SG1UVw>? NInwSYdqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MUKyN|U{ODd4OR?=
EN1 Mk\1SpVv[3Srb36gRZN{[Xl? NUe3fXJwPTByIH7N MnvuOUBl Mn7iSG1UVw>? M{jvPYlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MYqyN|U{ODd4OR?=
MFE296 NWD1SnVFTnWwY4Tpc44hSXO|YYm= M376bVUxOCCwTR?= MUi1JIQ> M1rt[2ROW09? MmfEbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? MonINlM2OzB5Nkm=
HASMCs NYHEWXVETnWwY4Tpc44hSXO|YYm= NH7LU5UxNTVyMDDuUS=> NXnWU4RGPiCm MXvkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> MkTNNlM2OTh2Nke=
U373 MoLPSpVv[3Srb36gRZN{[Xl? M2K5W|AvOjVxMD61M|Eh|ryP Mmj2NlQhcA>? MYnpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? MWGyN|Q4PDF5MR?=
ARN8  MmHMSpVv[3Srb36gRZN{[Xl? MYiwMlA2NTJizszN MX2yOEBp NVnnUW5LemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NXTFWmtOOjN2N{C1OFA>
MCF7 MWTGeY5kfGmxbjDBd5NigQ>? M{TY[VAvODVvMjFOwG0> NIHKXWczPCCq MWLy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> M2XjblI{PDdyNUSw
H1299  NVnLSnQxTnWwY4Tpc44hSXO|YYm= MWmwMlM{6oDVMdMgxtVO MnfONlQwPDhiaB?= M1KyUmROW09? NF7HO|RqdmO{ZXHz[ZMhTS2lYXTo[ZJqdiCycn;0[YlvKGyndnXsd{Bld3OnIHTldIVv\GWwdHz5 NWrOdJR2OjN2NkG5O|U>
H1299 NYXRVYNDTnWwY4Tpc44hSXO|YYm= MY[wMlUh|ryP NWHmW2pQPDhiaB?= NGHUe4NFVVOR MV7pcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu M2HHW|I{PDZzOUe1
H1299 M2fTZ2Z2dmO2aX;uJGF{e2G7 Ml64NE42KM7:TR?= MX[0PEBp MoO3SG1UVw>? NUjyOXJ2cW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= NGGxNVUzOzR4MUm3OS=>
MG-63  NV;WbmRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCwMlMh|ryP M2HROFEzNTl4IHi= MmTBSG1UVw>? MVrpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw M3zzXlI{PDVzOEG3
LM8 M2DCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofENE4{KM7:TR?= M{TaVFEzNTl4IHi= MljGSG1UVw>? M2PZPYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= NG\PfVAzOzR3MUixOy=>
K562 MXjGeY5kfGmxbjDBd5NigQ>? MV2wMlUh|ryP NFzGOZgzPCCq M1nwXIV1cGGwb3y= Mk\J[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> MU[yN|Q{ODl3Nx?=
HEL NEG3RZlHfW6ldHnvckBCe3OjeR?= MWSwMlUh|ryP MUiyOEBp NWjCbog{\XSqYX7vcC=> M4f3SIRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv NXGx[W1tOjN2M{C5OVc>
HL60 MYLBdI9xfG:|aYOgRZN{[Xl? NE\jeZMyKM7:TR?= MlThNlQhcA>? MnPsbY5lfWOnc9MgZ4VtdCCmZXH0bC=> M1;lR|I{PDByNUG5
KG1 NGGwVGFCeG:ydH;zbZMhSXO|YYm= NVXlSHNrOSEQvF2= NGXBSoMzPCCq M2PCOolv\HWlZYRCpINmdGxiZHXheIg> NHHaW4kzOzRyMEWxPS=>
Kazumi MUnBdI9xfG:|aYOgRZN{[Xl? NH3COXkyKM7:TR?= NEmwfIczPCCq MYfpcoR2[2W|wrDj[YxtKGSnYYTo MmfYNlM1ODB3MUm=
K562 MVTBdI9xfG:|aYOgRZN{[Xl? M4nUXVEh|ryP M3HzWVI1KGh? NFnzeGRqdmS3Y3XzxsBk\WyuIHTlZZRp NFr3c5YzOzRyMEWxPS=>
THP1 MX3BdI9xfG:|aYOgRZN{[Xl? NUTCSnpiOSEQvF2= M363TlI1KGh? MUXpcoR2[2W|wrDj[YxtKGSnYYTo M3vYO|I{PDByNUG5
SH-SY5Y NVWyWJNuTnWwY4Tpc44hSXO|YYm= MnzYNlUxKG6P M2\RfVE3KGh? MVjjbIFv\2W|IHX4dJJme3Orb36gdIF1fGW{bjDv[kBo\W6nczDpcpZwdH[nZDDpckBkcG:uZYP0[ZJwdCC|eX70bIV{cXNuIIXweIFs\SCjbnSg[YZndHW6 NFT2UZkzOzN{NkSyNi=>
HEK293 NFTT[IxHfW6ldHnvckBCe3OjeR?= MUKxJOK2VcLi MXWxPEBpyqB? M4DnOolvcGmkaYTzJJRp\SCtYXzpdolvNTdvbXXkbYF1\WRicnXjdpVqfG2nboSgc4Yhe3mwcHjpcIlvNTFiYXfndoVo[XSnczDpcpRwKGGpZ4Lld49u\XN? NXH3T|AxOjN{OES4OFg>
HTK NWK1Wlc3TnWwY4Tpc44hSXO|YYm= M1TnblQxOCCwTR?= NFLPRmc4OiCq M{fRfYlvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44> NXHPVZNQOjN{OESwNFI>
HTK M1PUNWZ2dmO2aX;uJGF{e2G7 MXuxNFAuQDBybl2= NWrzb5lPPzJiaB?= NWrMeWhE[myxY3vzJHRITi4QsvMAl2lv\HWlZXSgVm9UKGGwZDDINm8zyqCDY3P1cZVt[XSrb36= MWCyN|I5PDByMh?=
Caco-2  NFrBUlBHfW6ldHnvckBCe3OjeR?= MVexJOK2VcLi MWOyOEBp MkX0[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w NH\3[GwzOzF7NUC3NC=>
HeLa M4XVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:xNFAhdk1? MVSyOEBp NI\SXFhFVVOR MVHJR|UxKG:oIEGwNI5O NWTjSoxEOjNzNkW3OFg>
HeLa NYXVVJc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXkXppRPDBibl2= MkjmOFghcA>? MVTEUXNQ NHr0e2lKSzVyIH;mJFQxdk1? MnjrNlMyPjV5NEi=
HeLa MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rYcFIxKG6P NHKxTpM4OiCq M4jYb2ROW09? M{PiZ2lEPTBib3[gNlBvVQ>? NWjrfZY6OjNzNkW3OFg>
HeLa NGXYO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnIcVAyOC9|MD:1NEBvVQ>? M3nFUFczKGh? NX[4eVM1TE2VTx?= NYLJdmx1cW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 NXziXYVpOjNzNkW3OFg>
MDA-MB-231 NHTEbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvqNlUuPDByIH7N NVTmcY1SPDhiaB?= NVLlc|JPUUN3MDDv[kAzPjNwMn7NxsA> NGDHWZAzOzB3NUG5PC=>
MCF-7  MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHexd2UzPS12MECgcm0> NWDsPI84PDhiaB?= NWjCcXJSUUN3MDDv[kAzOjBwNH7N MWCyN|A2PTF7OB?=
ECC-1  NFK1eXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzme3gyODBibl2= M1PGTVI1KGh? NF7tNGVmfGijbn;s M3\ZUIlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= NUXtW4VsOjNyMki4NFM>
HEC-1A NWPRWYdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxNFAhdk1? Moi1NlQhcA>? NW\mdZQ{\XSqYX7vcC=> NFPxe4VqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|OTW= MmHMNlMxOjh6MEO=
NHAC-kn NFf1[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\iNVAwOTByL{WwNEBvVQ>? Mo\hNVIhcA>? M13je2ROW09? MmG1TWM2OCCxZjC1NFBvVQ>? NXTxVGI6OjNyMUe4O|E>
A549 MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTYc2wzPTBibl2= NHKwbXQ3NTd{IHi= NETXTolFVVOR MoTQZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> M2Dhd|IzQTl2N{iw
MG-63 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zZR|MxOCCwTR?= M1HBV|EzKGh? NV\oRmlOTE2VTx?= MmrybY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFg3LQ>? MWmyNlc6QTN|OB?=
MG-63 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPVe|E{ODBibl2= MW[yOEBp NELxXZpFVVOR MojKbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFY4LQ>? NWm2OVBIOjJ5OUmzN|g>
MG-63 M{nkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zObVMxOCCwTR?= NET3doM1QCCq NXXDTHNXTE2VTx?= M3r0cIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV? M3f0U|IzPzl7M{O4
HL60  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TmVFE2OC1|NUCgcm0> MUmyOEBp NWnYeYM1cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? M{T3SlIzPzV|N{O5
U937 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HHTVE2OC1|NUCgcm0> NFPFcYozPCCq NGi1VXNqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O M3;wdVIzPzV|N{O5
SCC-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2yNFAuOzJyMDDuUS=> M3\EUFEzNzJ2L{S4JIg> MkjhSG1UVw>? MnribY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhW0OFLU[gZ4VtdHNiaX6gZUBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NWnTVZFiOjJ3NUKzNlE>
U87  MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;obpd4OTByLUOwNEBv\w>? MlT0NlQhcA>? MmjDbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFczLSBiYYSgNlAxdmd? Ml3aNlIzPzB6NEm=
K562 NI[wRWdHfW6ldHnvckBCe3OjeR?= NX7KUWJROSEQvF2= MlrzNVIhcA>? M173dWROW09? M{XFS4VvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS M{DvZlIzOTd7MUm4
Reh NWrJbpVYTnWwY4Tpc44hSXO|YYm= NUnKPHg6OC5|L{Gg{txO MXGxNkBp M17Dd2ROW09? NIjVNY1mdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> M4XadVIzOTd7MUm4

... Click to View More Cell Line Experimental Data

In vivo試験 Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]
臨床試験
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

In vitro HDAC activity Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.

細胞アッセイ:

[1]

細胞株 MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
濃度 Dissolved in absolute ethanol, final concentrations ~10 μM
反応時間 96 hours
実験の流れ

Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.

動物実験:

[1]

動物モデル Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
製剤 Dissolved in DMSO
投薬量 ~5 mg/kg/day
投与方法 Injection s.c.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Trichostatin A (TSA) SDF
分子量 302.4
化学式

C17H22N2O3

CAS No. 58880-19-6
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 23 mg/mL (76.05 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (R,2E,4E)-6-(4-(dimethylamino)benzoyl)-N-hydroxy-4-methylhepta-2,4-dienamide

文献中の引用 (20)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related HDAC 阻害剤

  • LMK-235

    LMK-235は一種のHDAC4とHDAC5選択性阻害剤で、IC50値が11.9 nM と 4.2 nMに分かれます。

  • CAY10603

    CAY10603は一種の有効的で、選択性的なHDAC6阻害剤で、IC50値が2 pMになって、HDAC6に作用する選択性はHDACsに作用する選択性より200倍以上が高くなります。

  • 4SC-202

    4SC-202は一種の選択性I型HDAC阻害剤で、HDAC1、HDAC2とHDAC3に作用する時のIC50値が1.20 μM、1.12 μMと0.57 μMそれぞれに分かれて、Lysine specific demethylase 1 (LSD1)にも抑制活性を表します。臨床1期。

  • HPOB

    HPOBは一種の有効的で、選択性HDAC6阻害剤で、IC50値が56 nMになって、HDAC6に作用する選択性は他のHDACsに作用する選択性より30倍以上が高くなります。

  • Panobinostat (LBH589)

    Panobinostat (LBH589) は一種の新たで、広範なHDAC阻害剤で、無細胞試験でIC50値が5 nMです。臨床3期。

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA)は一種のHDAC阻害剤で、無細胞試験でIC50値が約10 nMです。

  • Entinostat (MS-275)

    Entinostat (MS-275)はHDAC1とHDAC3を強く抑制して、無細胞試験でIC50値が0.51μMと1.7μMに分かれて、抑制作用がHDACs 4/6/8/10より良くなリます。臨床3期。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)は一種の有効なHDAC1とHDAC2阻害剤で、無細胞試験でIC50値が36 nMと47 nMに分かれます。

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966は一種のHDAC3阻害剤で、無細胞試験でIC50値が0.08μMになって、HDAC3に作用する選択性が他のHDACに作用する選択性より200倍以上高くなります。

最近チェックしたアイテム

Tags: Trichostatin A (TSA)を買う | Trichostatin A (TSA)供給者 | Trichostatin A (TSA)を購入する | Trichostatin A (TSA)費用 | Trichostatin A (TSA)生産者 | オーダーTrichostatin A (TSA) | Trichostatin A (TSA)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ